Literature DB >> 10569791

Serum immunoglobulin response and protection from homologous challenge by Proteus mirabilis in a mouse model of ascending urinary tract infection.

D E Johnson1, F K Bahrani, C V Lockatell, C B Drachenberg, J R Hebel, R Belas, J W Warren, H L Mobley.   

Abstract

We tested the hypothesis that experimental Proteus mirabilis urinary tract infection in mice would protect against homologous bladder rechallenge. Despite production of serum immunoglobulin G (IgG) and IgM (median titers of 1:320 and 1:80, respectively), vaccinated (infected and antibiotic-cured) mice did not show a decrease in mortality upon rechallenge; the survivors experienced only modest protection from infection (mean log(10) number of CFU of P. mirabilis Nal(r) HI4320 per milliliter or gram in vaccinated mice versus sham-vaccinated mice: urine, 100-fold less [3.5 versus 5.5; P = 0.13]; bladder, 100-fold less [3.1 versus 5.1; P = 0.066]; kidneys, 40-fold less [2.7 versus 4.3; P = 0.016]). Western blots using protein from the wild-type strain and isogenic mutants demonstrated antibody responses to MR/P and PMF fimbriae and flagella. There was no correlation between serum IgG or IgM levels and protection from mortality or infection. There was a trend toward elevated serum IgA titers and protection from subsequent challenge (P >/= 0.09), although only a few mice developed significant serum IgA levels. We conclude that prior infection with P. mirabilis does not protect significantly against homologous challenge.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10569791      PMCID: PMC97083          DOI: 10.1128/IAI.67.12.6683-6687.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

2.  Urease. The primary cause of infection-induced urinary stones.

Authors:  D P Griffith; D M Musher; C Itin
Journal:  Invest Urol       Date:  1976-03

3.  A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters.

Authors:  J W Warren; J H Tenney; J M Hoopes; H L Muncie; W C Anthony
Journal:  J Infect Dis       Date:  1982-12       Impact factor: 5.226

4.  Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination.

Authors:  S Langermann; S Palaszynski; M Barnhart; G Auguste; J S Pinkner; J Burlein; P Barren; S Koenig; S Leath; C H Jones; S J Hultgren
Journal:  Science       Date:  1997-04-25       Impact factor: 47.728

5.  The combination of pivampicillin and pivmecillinam versus pivampicillin alone in the treatment of acute pyelonephritis.

Authors:  S Eriksson; J Zbornik; H Dahnsjö; P Erlanson; O Kahlmeter; H Fritz; C A Bauer
Journal:  Scand J Infect Dis       Date:  1986

6.  The special affinity of particular types of Proteus mirabilis for the urinary tract.

Authors:  B W Senior
Journal:  J Med Microbiol       Date:  1979-02       Impact factor: 2.472

7.  Efficacy of a Proteus mirabilis outer membrane protein vaccine in preventing experimental Proteus pyelonephritis in a BALB/c mouse model.

Authors:  N Moayeri; C M Collins; P O'Hanley
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

8.  Construction of an MR/P fimbrial mutant of Proteus mirabilis: role in virulence in a mouse model of ascending urinary tract infection.

Authors:  F K Bahrani; G Massad; C V Lockatell; D E Johnson; R G Russell; J W Warren; H L Mobley
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

9.  Proteus morgani is less frequently associated with urinary tract infections than Proteus mirabilis--an explanation.

Authors:  B W Senior
Journal:  J Med Microbiol       Date:  1983-08       Impact factor: 2.472

10.  Timentin versus piperacillin in the therapy of serious urinary tract infections.

Authors:  T M File; J S Tan; S J Salstrom; L Johnson
Journal:  Am J Med       Date:  1985-11-29       Impact factor: 4.965

View more
  6 in total

Review 1.  Host-pathogen interactions in urinary tract infection.

Authors:  Greta R Nielubowicz; Harry L T Mobley
Journal:  Nat Rev Urol       Date:  2010-07-20       Impact factor: 14.432

Review 2.  Pathogenesis of Proteus mirabilis Infection.

Authors:  Chelsie E Armbruster; Harry L T Mobley; Melanie M Pearson
Journal:  EcoSal Plus       Date:  2018-02

3.  Zinc uptake contributes to motility and provides a competitive advantage to Proteus mirabilis during experimental urinary tract infection.

Authors:  Greta R Nielubowicz; Sara N Smith; Harry L T Mobley
Journal:  Infect Immun       Date:  2010-04-12       Impact factor: 3.441

4.  Development of an intranasal vaccine to prevent urinary tract infection by Proteus mirabilis.

Authors:  Xin Li; C Virginia Lockatell; David E Johnson; M Chelsea Lane; John W Warren; Harry L T Mobley
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

5.  Outer membrane antigens of the uropathogen Proteus mirabilis recognized by the humoral response during experimental murine urinary tract infection.

Authors:  Greta R Nielubowicz; Sara N Smith; Harry L T Mobley
Journal:  Infect Immun       Date:  2008-07-14       Impact factor: 3.441

Review 6.  Proteus mirabilis and Urinary Tract Infections.

Authors:  Jessica N Schaffer; Melanie M Pearson
Journal:  Microbiol Spectr       Date:  2015-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.